KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EBITDA: 2016-2024

Historic EBITDA for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $249.3 million.

  • Amneal Pharmaceuticals' EBITDA fell 20.79% to $70.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $357.9 million, marking a year-over-year increase of 90.63%. This contributed to the annual value of $249.3 million for FY2024, which is 21.99% up from last year.
  • Amneal Pharmaceuticals' EBITDA amounted to $249.3 million in FY2024, which was up 21.99% from $204.4 million recorded in FY2023.
  • Amneal Pharmaceuticals' EBITDA's 5-year high stood at $249.3 million during FY2024, with a 5-year trough of -$94.9 million in FY2022.
  • For the 3-year period, Amneal Pharmaceuticals' EBITDA averaged around $119.6 million, with its median value being $204.4 million (2023).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' EBITDA tumbled by 162.16% in 2022, and later surged by 315.29% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' EBITDA stood at $91.2 million in 2020, then soared by 67.53% to $152.7 million in 2021, then crashed by 162.16% to -$94.9 million in 2022, then soared by 315.29% to $204.4 million in 2023, then rose by 21.99% to $249.3 million in 2024.